about
Neuromedin U: a multifunctional neuropeptide with pleiotropic rolesSurvivin: role in normal cells and in pathological conditionsIsosteviol has beneficial effects on palmitate-induced α-cell dysfunction and gene expressionThe development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line.Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.ISEV position paper: extracellular vesicle RNA analysis and bioinformatics.Three-dimensional cell culture: the missing link in drug discovery.Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.Predictive biomarkers for dasatinib treatment in melanoma.Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.Investigation of the molecular profile of basal cell carcinoma using whole genome microarraysBiological properties of extracellular vesicles and their physiological functions.Characterisation of BHK-21 cells engineered to secrete human insulin.Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.Biomarkers and multiple drug resistance in breast cancer.Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance.SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissueDrug resistance in cancer - searching for mechanisms, markers and therapeutic agents.Molecular medicine of microRNAs: structure, function and implications for diabetes.Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesBreast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine.Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.Intracellular and extracellular microRNAs in breast cancer.Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue.A microarray approach to translational medicine in breast cancer: how representative are cell line models of clinical conditions?The Role of Exosomes in Breast Cancer.Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.Blood-Based Biomarkers for Metabolic Syndrome.Expanding on exosomes and ectosomes in cancer.Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine.Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors.Receptor tyrosine kinase targeting in multicellular spheroids.Analysis of changes in phosphorylation of receptor tyrosine kinases: antibody arrays.miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
P50
Q28087208-DDE98BBD-0FCC-4B62-A7C1-198C8ECA1D86Q28188930-86825FFE-06B2-45B3-9003-0188B30F15D9Q28481674-B0FD4549-AF34-4CDB-B14A-BD13B0E2EFCCQ33243793-2EDF464E-27FB-4958-B420-97702737B80AQ33474188-9DF9423C-D9E8-4CFE-98E7-8CF63B9A934FQ33783032-A94AF7D1-8824-41AE-A92F-23078475C335Q34394843-CB15E67E-0F3D-4230-A7FE-1B078DB7A177Q34448808-6C8FF5C1-81FA-49E6-A6BA-2CFB76C3E129Q34516014-D38EBE71-0FFE-462C-BA89-701A8A2B63C8Q34524533-04B9D8C5-7D97-4E8C-96E7-90D11A3648CAQ34781153-6E14F36D-05BC-4EF9-BDD8-E5AF8167337AQ35462077-C4E64272-1F71-4AC9-B6FC-271829FDAAC4Q35589231-BB2D2B0D-F881-4A18-AC4A-55F256E05C4DQ35611763-EF49F8DA-C79C-4829-8DC3-246984F2B236Q36255148-F978E7DF-3EF5-4721-AF9C-A3652C9AB3FEQ36422761-08F0111C-E61D-458D-8222-CB032946B371Q36544974-68BC802B-1340-426A-B61E-7B0F87DF6D6DQ36569839-D61208E6-A5C3-4295-AE97-FCA63AD1171BQ36619756-BFC0145B-7310-45CB-A255-DD413D5CF995Q36667529-F8CA4187-D389-41B6-8DBE-2A154FC41163Q37008882-200197B8-8913-4C9C-9138-7F5F2969B306Q37243359-D8569FBB-D8EB-44E7-9AA8-5478D4A9FCB9Q37269217-1F665618-6181-466C-A796-7603FE06B2D5Q37481556-00D3B04B-B8A7-438E-AF0D-219B084CEC24Q37548836-8704076C-A2A9-4049-A4F8-5A3AAD5D7BC4Q37808080-0E5CC532-7940-439F-8E8F-BDBDA1038ADCQ38269343-7C03A480-7D7D-410C-87E6-550AA500EA71Q38348297-2AF96030-5696-4D33-841F-F0B1B7D77353Q38479313-701E782C-6447-42D3-8BD2-6CCA7E2547B5Q38515941-44169B8F-B12B-4893-8004-B53ACAEFF3F3Q38607305-C7CD8BE9-D15F-4F2E-9D6F-78D131485B13Q38718320-EF1EED50-CCEA-4F77-948C-93EC413DB2F3Q38826988-35E5B93B-A9C0-4168-ABE8-D218FC2B7D43Q38865369-7094F1B6-FF08-45B6-81FD-EB3098487670Q38894992-5A63F250-BF8F-4844-B72C-2C544BBE4F43Q38947411-4BC3CFAD-449C-40C3-B19B-C6111757C069Q38947415-9EE741ED-E549-40DE-8175-962FFAF10020Q38947445-F56B9F58-A9E7-4E73-B201-42E8207154C8Q38972595-DBF64BE2-7D8C-46D4-A5E4-7A1E8EB6ADC1Q38990224-27F7627C-757A-436D-B51D-0714A6AC7810
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lorraine O'Driscoll
@ast
Lorraine O'Driscoll
@en
Lorraine O'Driscoll
@es
Lorraine O'Driscoll
@nl
Lorraine O'Driscoll
@sl
type
label
Lorraine O'Driscoll
@ast
Lorraine O'Driscoll
@en
Lorraine O'Driscoll
@es
Lorraine O'Driscoll
@nl
Lorraine O'Driscoll
@sl
prefLabel
Lorraine O'Driscoll
@ast
Lorraine O'Driscoll
@en
Lorraine O'Driscoll
@es
Lorraine O'Driscoll
@nl
Lorraine O'Driscoll
@sl
P106
P1153
6603791908
P21
P31
P496
0000-0002-9860-8262